MCL1 Inhibitor Combination Therapy for the Treatment of Melanoma

Description:

Melanoma causes the majority of skin cancer related deaths in the US despite only accounting for 1% of skin cancer cases. Immunotherapy has improved survival for melanoma patients, however 50% of these individuals will be refractory to first line treatment. Dr. Shellman and her team at the University of Colorado have identified a MCL1 inhibitor-immunotherapy combination therapy that may be effective in treatment resistant and refractory melanoma. In addition, uveal melanoma is identified as a particularly susceptible melanoma subtype to MCL1 inhibitor alone due to their unique expression of BFL1 and PUMA.

Download Summary Document Here:

http://cuamc.technologypublisher.com/files/sites/cu4999h_ncs_updated.pdf

Direct Link:

http://cuamc.technologypublisher.com/technology/48164

Category:

Therapeutics